不依赖血培养的血流感染全血直接分子鉴定:已知感染状态标本的前瞻性评估
该研究评估了RaPID/BSI直接-from-specimen分子检测的性能,该检测通过选择性裂解宿主及非活性微生物细胞的前处理步骤,仅检测血液中可存活微生物的基因组物质,以减少分子方法常见的假阳性。研究显示该检测不受宿主免疫细胞及高浓度常用抗菌药物干扰,并在已知脓毒症/BSI状态个体的前瞻性队列预试验中验证了准确性。该检测周转时间约4小时,有助于快速精准诊断和抗菌药物管理。
要点
- RaPID/BSI分子检测通过选择性裂解前处理仅检测可存活微生物,降低假阳性。
- 该检测不受宿主免疫细胞及高浓度常用抗菌药物干扰。
- 前瞻性队列预试验纳入已知脓毒症/BSI状态个体,验证了检测准确性。
核心结论
- RaPID/BSI直接-from-specimen分子检测通过选择性裂解前处理,可减少分子方法常见的假阳性,并在已知感染状态个体的前瞻性队列预试验中显示准确性。
研究设计与样本
- 前瞻性队列预试验,纳入已知脓毒症/BSI状态的个体,包括阳性和阴性样本。
主要发现
- 该检测不受宿主免疫细胞和常用抗菌药物高浓度干扰。
- 在已知脓毒症/BSI状态个体的前瞻性队列预试验中验证了该技术的准确性。
关键数值与推荐
- 血培养作为诊断金标准,周转时间为1-7天,具体取决于微生物。
- RaPID/BSI检测的周转时间约为4小时。
临床怎么用
- 该检测周转时间约4小时,可显著缩短至适当精准诊断 causative 微生物的时间。
- 短周转时间允许近乎实时追踪血液中病原体清除情况或判断是否需要更换抗菌方案,有助于优化抗菌药物管理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Sepsis caused by bloodstream infection (BSI) is a major healthcare burden and a leading cause of morbidity and mortality worldwide. Timely diagnosis is critical to optimize clinical outcome, as mortality rates rise every hour treatment is delayed. Blood culture remains the "gold standard" for diagnosis but is limited by its long turnaround time (1-7 days depending on the organism) and its potential to provide false-negative results due to interference by antimicrobial therapy or the presence of mixed (i.e., polymicrobial) infections. In this paper, we evaluated the performance of resistance and pathogen ID/BSI, a direct-from-specimen molecular assay. To reduce the false-positivity rate common with molecular methods, this assay isolates and detects genomic material only from viable microorganisms in the blood by incorporating a novel precursor step to selectively lyse host and non-viable microbial cells and remove cell-free genomic material prior to lysis and analysis of microbial cells. Here, we demonstrate that the assay is free of interference from host immune cells and common antimicrobial agents at elevated concentrations. We also demonstrate the accuracy of this technology in a prospective cohort pilot study of individuals with known sepsis/BSI status, including samples from both positive and negative individuals. IMPORTANCE: Blood culture remains the "gold standard" for the diagnosis of sepsis/bloodstream infection (BSI) but has many limitations which may lead to a delay in appropriate and accurate treatment in patients. Molecular diagnostic methods have the potential for markedly improving the management of such patients through faster turnaround times and increased accuracy. But molecular diagnostic methods have not been widely adopted for the identification of BSIs. By incorporating a precursor step of selective lysis of host and non-viable microorganisms, our resistance and pathogen ID (RaPID)/BSI molecular assay addresses many limitations of blood culture and other molecular assay. The RaPID/BSI assay has an approximate turnaround time of 4 hours, thereby significantly reducing the time to appropriate and accurate diagnosis of causative microorganisms in such patients. The short turnaround time also allows for close to real-time tracking of pathogenic clearance of microorganisms from the blood of these patients or if a change of antimicrobial regimen is required. Thus, the RaPID/BSI molecular assay helps with optimization of antimicrobial stewardship; prompt and accurate diagnosis of sepsis/BSI could help target timely treatment and reduce mortality and morbidity in such patients.
引用
- Iyer V, Castro D, Malla B, et al. Culture-independent identification of bloodstream infections from whole blood: prospective evaluation in specimens of known infection status. J Clin Microbiol. 2024. PMID: 38315022. doi:10.1128/jcm.01498-23
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。